Type Fasting and Cancer into a search engine and you will find hundreds (if not thousands) of ‘opinions’ online, many of them from people not even qualified to give medical opinions.
There has been a lot of research done by The Longevity Institute to explore the impact of fasting and fast-mimicking diets on cancer. They have shown that it works in the lab, and in 2015 they showed it works in mice. While animal models and in vitro studies indicate promising results, the translation to human trials is complex, with various types of cancer responding differently to dietary interventions. They have not, over the last 10 years, been able to replicate this success in humans with cancer. It is noticeable that they have stepped back from their promotion of fasting as a potential cancer treatment and focus on its possible role in anti-ageing and reducing risk of getting cancer.
https://www.thelongevityinstitute.health
The Warburg effect – what is it?
Cancer cells exhibit a phenomenon commonly known as the Warburg effect, where they rely on glycolysis for energy production, even in the presence of oxygen. This metabolic reprogramming permits cancer cells to generate energy rapidly, which is important to sustain their rapid growth and proliferation. The Warburg Effect was first described in the 1920s.
The Warburg Effect has been misinterpreted by the ‘How to Starve Cancer’ and the ‘Sugar Feeds Cancer’ movements. They take a simplistic view that because cancer cells use glucose, the act of removing the glucose supply will kill the cancer cells. This works in isolation on individual cells in a petri dish, but not in the human body, where the tumour microenvironment (TME) is far more complex. In the past 100 years of cancer research, glucose restriction has not resulted in an effective treatment for cancer. Every cell in our body is dependent upon glucose as a fuel, starving the body of its fuel will affect all cells, including the ones that fight the cancer.
What does that mean?
There are many things that will kill a cancer cell in the isolated, controlled environment of a petri dish. However, cancer cells in the human body have a totally different context, they are communicating and reacting to the cells and signals all around them. The majority of anti-cancer mechanisms identified in the laboratory never translate into effective treatments because the petri-dish cannot replicate the complexity of the tumour microenvironment.
Clinical evidence in humans remains limited. Fasting is not yet a proven or standardized therapy. It can also pose risks, especially for individuals who are underweight, malnourished, or undergoing intensive treatments.
Cachexia and Sarcopenia are both weight loss syndromes associated with cancer and cancer treatment.
https://www.cancerresearchuk.org/about-cancer/coping/physically/diet-problems/types/cachexia
https://bestpractice.bmj.com/topics/en-gb/3000319
In summary, fasting shows preliminary ‘potential’ as an adjunct approach in cancer care from the point of view of treatment tolerance and reduced fatigue as reported in some small studies. More large-scale, controlled human trials are needed before fasting can be safely and effectively integrated into standard oncology practice.